WPRIM Management System> DCMS> Journal of Clinical Hepatology> 2023> 39> 5

Volume: 39 Issue: 5

1. Application and prospect of cell therapy in clinical treatment of liver diseases Page:1001—1003
2. ｜Baveno Ⅶ algorithm outperformed other models in ruling out high-risk varices in individuals with HBV-related cirrhosis Page:1003—1003
3. Clinical research advances in mesenchymal stem cells for the treatment of autoimmune liver diseases Page:1004—1009
4. Clinical research advances in mesenchymal stem cells for the treatment of end-stage liver disease Page:1010—1018
5. Clinical research advances in chimeric antigen receptor T-cell therapy for primary liver cancer Page:1019—1029
6. Research advances in tumor-infiltrating lymphocytes in treatment of biliary tract cancer Page:1030—1036
7. Opinion on the definition of "occult hepatitis B virus infection" Page:1037—1040
8. Diagnosis and treatment guideline for Chinese Medicine on non-alcoholic steatohepatitis Page:1041—1048
9. A brief introduction of AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease in 2023 Page:1049—1055
10. Seroepidemiological characteristics of hepatitis B virus among hospitalized patients aged 18 years or below in Henan Province of China Page:1056—1060
11. Current reviewers Page:1060—1060
12. Efficacy and safety of tenofovir alafenamide fumarate in treatment of chronic hepatitis B patients aged ≥60 years in Qingdao, China Page:1061—1069
13. Value of combined baseline serum HBV markers in predicting HBeAg seroconversion in chronic hepatitis B patients treated by nucleos(t)ide analogues Page:1070—1075
14. Epidemiological situation of hepatitis D in the gathering area of Mongolian population in Inner Mongolia Autonomous Region of China Page:1076—1080
15. Influencing factors for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus Page:1081—1088
16. Establishment and evaluation of a multivariate Cox proportional-hazards prediction model for mortality during short-term hospitalization in patients with liver cirrhosis and sepsis Page:1089—1097
17. Value of Charlson comorbidity index in predicting the prognosis of patients with acute-on-chronic liver failure Page:1098—1104
18. Etiological spectrum and clinical features of patients with unexplained liver disease manifesting as isolated jaundice: An analysis of 91 cases Page:1105—1109
19. Effect of Toll-like receptor 4 on liver regeneration during acetaminophen-induced liver injury in mice Page:1110—1118
20. Mechanism of action of Dange Jiecheng decoction in a rat model of alcoholic liver disease based on the Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 signaling pathway Page:1119—1125
21. Effect of Yinchenhao decoction on renal oxidative stress injury in rats with obstructive jaundice and its mechanism of action based on the nuclear factor erythroid 2-related factor 2 signaling pathway Page:1126—1133
22. Conference announcement｜EASL Congress(2023) Page:1133—1133
23. Role of the Sonic Hedgehog signaling pathway in intestinal mucosal barrier injury in rats with severe acute pancreatitis Page:1134—1143
24. ｜Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection Page:1143—1143
25. Histopathological characteristics of the liver in children with non-alcoholic fatty liver disease Page:1144—1149
26. Autoimmune hepatitis-primary biliary cholangitis overlap syndrome with gastric adenocarcinoma: A case report Page:1150—1153
27. A case of atypical hepatic hemangioma misdiagnosed as hepatic cystadenoma Page:1154—1156
28. Endoscopic retrograde cholangiopancreatography combined with peroral choledochoscopy in treatment of common bile duct stones with gallbladder neck stones and gallbladder polyps: A case report Page:1157—1161
29. Mucinous gallbladder adenoma diagnosed by endoscopic retrograde cholangiopancreatography and SpyGlass: A case report Page:1162—1165
30. Association between bile acids and nonalcoholic fatty liver disease Page:1166—1171
31. ｜Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease Page:1171—1171
32. Role of bone morphogenetic protein-4 in the pathogenesis of nonalcoholic fatty liver disease Page:1172—1177
33. Advances in the application of nonselective β-receptor blockers in treatment of liver cirrhosis Page:1178—1183
34. Current research status of spleen stiffness measurement in predicting portal hypertension and its complications in patients with liver cirrhosis Page:1184—1190
35. Current research status of prognostic models for transjugular intrahepatic portosystemic shunt Page:1191—1196
36. Research advances in immunotherapy for hepatocellular carcinoma Page:1197—1203
37. Role of macrophage polarization and its crosstalk with neighboring cells in hepatocellular carcinoma Page:1204—1211
38. Research advances in tumor-associated macrophages in hepatocellular carcinoma microenvironment Page:1212—1218
39. Methods for evaluating liver reserve function before hepatectomy Page:1219—1226
40. Research advances in acute pancreatitis-associated ascites fluid Page:1227—1233
41. Role of thymoquinone in treatment of pancreatic cancer Page:1234—1244

©2019 - Present World Health Organization Regional Office for the Western Pacific. All Rights Reserved.